Abstract Number: 2442 • 2018 ACR/ARHP Annual Meeting
Familial Mediterranean Fever Associated Infertility and Underlying Factors with Fertility
Background/Purpose: Familial Mediterranean Fever (FMF) is the most frequent auto-inflammatory disease caused by MEFV gene mutations. Although disease is characterized by intermittent febrile inflammatory attacks…Abstract Number: 2443 • 2018 ACR/ARHP Annual Meeting
Trends in the Incidence of Lymphomas and Leukemias in Patients with Rheumatoid Arthritis in Spain: An Observational Cohort Study of Hospital Discharges from 1999 to 2015
Background/Purpose: Oncohematological diseases have an increased incidence in Rheumatoid Arthritis (RA) patients. In the last years numerous studies have appeared exploring the relationship between these…Abstract Number: 2444 • 2018 ACR/ARHP Annual Meeting
The Risk of Solid Cancers in Patients with Rheumatoid Arthritis Exposed to Biologic Dmards with/without Prior Cancers
Background/Purpose: To compare the risk of solid cancer in patient with rheumatoid arthritis treated with biologic disease modifying antirheumatic drugs(b-DMARDs) to that in patients treated…Abstract Number: 2445 • 2018 ACR/ARHP Annual Meeting
The Effect of Biologic Agents on Hemoglobin Levels of Patients with Rheumatoid Arthritis
Background/Purpose: Anemia is not considered a major problem in rheumatoid arthritis. But prevalence data suggest that 30-70% of rheumatoid arthritis(RA) patients have anemia. Inflammatory cytokines…Abstract Number: 2446 • 2018 ACR/ARHP Annual Meeting
The Combined Use of Folic Acid Influenced the Time until the Development of Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis during Treatment with Methotrexate
Background/Purpose: Lymphoproliferative disorders (LPDs) are a serious complication in patients with rheumatoid arthritis (RA). Methotrexate (MTX) is known to be able to cause a development…Abstract Number: 2447 • 2018 ACR/ARHP Annual Meeting
Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs
Background/Purpose: Non-alcoholic fatty liver disease, characterized by hepatic steatosis (HS), is a very common form of chronic liver disease in many countries. Limited data are…Abstract Number: 2448 • 2018 ACR/ARHP Annual Meeting
Correlation between Long-Term Low-Dose Steroid Administration and Reactivation of Hepatitis B Virus in Patients with Rheumatoid Arthritis
Background/Purpose: It is well known that the use of corticosteroids results in increased viral replication and elevated ALT in patients with hepatitis B virus. The…Abstract Number: 2449 • 2018 ACR/ARHP Annual Meeting
Prevalence and Risk Factors of Serious Infections in Rheumatoid Arthritis Patients Receiving the Biologic/Targeted Synthetic Dmards: A Propensity Score Analysis from the Hong Kong Biologics Registry
Background/Purpose: To study the prevalence and risk factors for serious infections (SIs) in rheumatoid arthritis (RA) patients receiving the biologic / target synthetic (b/ts) DMARDs.…Abstract Number: 2450 • 2018 ACR/ARHP Annual Meeting
Prosthetic Joint Infection in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have been shown to have an increased susceptibility to the development of prosthetic joint infection (PJI) after Total Hip…Abstract Number: 2451 • 2018 ACR/ARHP Annual Meeting
Herpes Zoster in Rheumatoid Arthritis. Prospective Single Center Study of 390 RA Patients for 5 YEARS
Background/Purpose: Immunosuppressed patients such as Rheumatoid Arthritis (RA) patients have a greater risk (1.5-2 times) of presenting herpes zoster (HZ). Both, the disease itself and…Abstract Number: 2452 • 2018 ACR/ARHP Annual Meeting
Incidence Rate and Clinical Characteristics of Herpes Zoster Infection in Korean Patients with Rheumatoid Arthritis Patients
Background/Purpose: Herpes zoster (HZ) infection is not uncommon in rheumatoid arthritis (RA) patients, especially in those treated with biologic or targeted synthetic (bts) disease-modifying antirheumatic…Abstract Number: 2453 • 2018 ACR/ARHP Annual Meeting
Staphylococcus Aureus Carriage Rates Are High in Rheumatoid Arthritis Patients on Biologics
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher risk of surgical site infection than patients with osteoarthritis (OA). Disease modifying therapy is widely used…Abstract Number: 2454 • 2018 ACR/ARHP Annual Meeting
Virus Reactivation Rate in Rheumatoid Arthritis Using Tofacitinib
Background/Purpose: Although the increase in the incidence of Herpes Zoster by tofacitinib(TOF) in rheumatoid arthritis (RA) is well known, the reactivation rate of other viruses…Abstract Number: 2455 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Biologic and Non-Biologic Dmards
Background/Purpose: Individuals with rheumatoid arthritis (RA) have an increased risk of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), compared with…Abstract Number: 2456 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients in Truven Marketscan Data (Jan 2010–Sept 2015) Treated with Biologic or Conventional Dmards
Background/Purpose: Patients with RA have an increased risk of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT) compared to non-RA populations1. …
ACR Meeting Abstracts